Mononuclear cell complement receptor blockade in primary biliary cirrhosis

M N A AL-AGHBAR, J NEUBERGER, ROGER WILLIAMS, AND A L W F EDDLESTON

From the Liver Unit, King’s College Hospital and Medical School, Denmark Hill, London

SUMMARY Peripheral blood monocyte and lymphocyte receptors for Fc and C3b fragments were examined in vitro in patients with primary biliary cirrhosis and other chronic liver diseases using sheep red blood cells coated with anti-SRBC IgG1 (to detect Fc receptors) and with anti-SRBC IgM and complement (to detect C3b receptors). The number of C3b receptors detected on 100 monocytes was significantly lower in patients with primary biliary cirrhosis (23·0±12·0, mean±1 SD) compared with normal controls (57·4±16·9) and other chronic liver disease (HBsAg negative chronic active hepatitis 62·0±17·0, alcoholic cirrhosis 50·9±4·0), while the number of Fc receptors detected on 100 monocytes was not significantly different in all the groups (primary biliary cirrhosis 72·8±28·6, chronic active hepatitis 74·7±14·0, alcoholic cirrhosis 58·0±13·5 and normal controls 69·6±19·9). When mononuclear cells isolated from normal individuals were pre-incubated with serum from patients with primary biliary cirrhosis before testing their receptor function there was a significant reduction in the number of C3b receptors detected per 100 monocytes (27·6±10·8) compared with pre-incubation with normal serum (72·0±18·0). This reduction in C3b-receptor function was again observed when the serum used for pre-incubation was depleted of circulating immune complexes; but when complement was further depleted from these sera, the number of C3b-receptors detected after pre-incubation was similar to normal values (64·0±11·8). Lymphocyte receptors showed a similar pattern of results. This implies a specific C3b receptor blockade on monocytes and lymphocytes from patients with primary biliary cirrhosis which appears to be because of blocking by serum factor(s) including complement fragments.

Numerous abnormalities of immune function have been reported in patients with primary biliary cirrhosis. These include hypergammaglobulinaemia especially of IgM, raised levels of circulating immune complexes, anergy and impaired suppressor cell function for both T-B and T-T cellular interactions.1 The extent to which these abnormalities may contribute either to the pathogenesis or to the progression of the disease is not clear. A further abnormality is an impairment of the reticulo-endothelial system. Jaffe and his colleagues2 studied the clearance of autologous radio-chromium labelled red cells in patients with primary biliary cirrhosis and other chronic liver diseases and found a specific defect in the C3b-receptor mediated clearance of red cells only in patients with primary biliary cirrhosis. The clearance of IgG-coated red cells and aggregated albumin particles was normal, implying that these patients have a normal clearance of Fc receptor-mediated particles and immunologically inert particles.

As the failure of clearance of C3b-coated red cells in vivo could be because of blocking of C3b-receptors by serum factors, the present study was designed to examine directly in vitro Fc and C3b-receptors on the peripheral blood mononuclear cells in patients with primary biliary cirrhosis and other chronic liver diseases, including autoimmune chronic active hepatitis.

Methods

SUBJECTS

Ten healthy laboratory volunteers, seven of whom
were men, served as normal controls. None had a history of excess alcohol ingestion or previous hepatitis. The mean age was 30 years (range 28–41 years). Of the 13 patients with primary biliary cirrhosis investigated all had liver histology diagnostic of the disease. Four patients were in the early stages of primary biliary cirrhosis (stage I and II) and the remainder were in the late stages (III and IV). Twelve were women and the median age was 59 years (range 34–70 years). Four patients were taking d-Penicillamine 1-2 g daily in a controlled clinical trial and the remainder were not receiving any specific immunomodulatory drugs at the time of the study.

Nine patients with HBsAg negative chronic active hepatitis were studied. The diagnosis was made on internationally agreed histological criteria and all had established cirrhosis. Eight of these patients were men and ages ranged from 30 to 72 years (median 50 years). One patient was not receiving any specific therapy at the time of the study and the remaining eight were taking prednisolone 10–20 mg daily and azathioprine 75 mg daily.

Nine patients with alcoholic liver disease were studied; all were men and the median age was 57 years (range 39–78 years). All had taken more than 100 g ethanol daily for more than four years and all had features of alcoholic cirrhosis on liver biopsy. Patients were studied after a minimum period of two weeks as hospital inpatients during which time they had abstained from alcohol.

**ISOLATION OF PERIPHERAL BLOOD MONOCYTES**

Peripheral blood mononuclear cells were isolated from whole blood by dextran sedimentation and Ficoll-Triosil density centrifugation. Mononuclear cell-enriched plasma was then incubated in a Petri dish (Sterilin) for 45 minutes at 37°C to allow adherence of monocytes. The supernatant was discarded and the adherent cells were gently harvested using a rubber policeman. The cells were then washed three times in Hank’s balanced salt solution (Wellcome Reagents Ltd) and resuspended at a concentration of 10⁶ cells/ml in 20% heat inactivated fetal calf serum (Gibco) and RPMI 1640 (Gibco) containing L-glutamine, penicillin 200 IU/ml, streptomycin 100 μg/ml and amphotericin (Squibb) 2 μg/ml. In order to prevent adherence of monocytes to the test tubes, siliconised glass tubes were used throughout prepared by treating the tubes with Repelcote (Hopkin and Williams). At the end of the isolation procedure the median purity of monocytes was 46% (range 40–50%) as measured by peroxidase staining, and the viability as determined by trypan blue exclusion was greater than 95%.

**OPSONISATION OF SHEEP RED BLOOD CELLS WITH ANTI-SRBC-IgG (SRBC-IgG)**

Sheep red blood cells in Alsevers solution (Tissue Culture Services Ltd) were washed three times in 0.9% sodium chloride and diluted to give a final concentration of 2.5×10⁹/ml. The suboptimal agglutinating concentration of anti-SRBC-IgG (Sera Laboratories Ltd) was determined by titration. Equal volumes of sheep red blood cells and anti-SRBC-IgG were mixed and incubated for 30 minutes at 37°C. The coated sheep red cells were then washed three times in 0.9% sodium chloride and resuspended in the original volume.

**OPSONISATION OF SHEEP RED BLOOD CELLS BY ANTI-SRBC-IgM AND COMPLEMENT (SRBC-M-C)**

The suboptimal agglutinating concentration of anti-SRBC-IgM (Sera Laboratories Ltd) was determined by titration and was used to coat the sheep red blood cells as described above. These cells were then coated with complement using equal volumes of IgM coated sheep red blood cells and fresh human serum, used at a dilution of subminimal lysis, by incubating at 37°C for 30 minutes. The SRBC-M-C were then washed three times in 0.9% sodium chloride and resuspended to the original volume.

**ASSAY OF MONOCYTE RECEPTOR FUNCTION**

Round glass cover slips 13 mm diameter (Chance Poppers) were placed in each well of a multi-well tissue culture plate 2 cm² in diameter (Falcon). Five hundred microlitres of monocyte-enriched suspension (at 10⁶ cells/ml) were placed on the cover slip and incubated for 45 minutes at 37°C to allow adherence of the monocytes to the cover slips. One hundred microlitres of either sheep red blood cells, SRBC-IgG, SRBC-M or SRBC-M-C (at a concentration of 250×10⁶ cells/ml) was then added to each well in duplicate and incubated for 30 minutes at 37°C in humidified atmosphere containing 5% carbon dioxide, 12% oxygen, and 83% nitrogen. The non-adherent cells were removed by gentle washing of the cover slips in 0.9% sodium chloride, the remaining cells were fixed with 100% methanol, stained with 10% Giemsa, washed in water, dried in air, and fixed on glass slides. Monocytes were identified morphologically and the number of sheep red blood cells attached to 100 monocytes were counted in four random fields without the observer having knowledge of the nature of the cells on the slide.

**INCUBATION OF SERUM WITH PERIPHERAL BLOOD MONOCYTES**

In order to study the effect of prior incubation of serum with peripheral blood monocytes on receptor
function of monocytes from normal individuals, blood was withdrawn from patients with primary biliary cirrhosis and normal controls and allowed to clot for two hours at 37°C, the serum was removed by 10 minutes centrifugation at 1100 g and stored at -20°C. Monocyte enriched suspension from normal controls (at a concentration of 10^6/ml) was divided into two aliquots, which were incubated for 30 minutes at 37°C in a 2:1 v/v dilution of serum from either normal subjects or patients with primary biliary cirrhosis. The cells were then washed three times in Hank's balanced salt solution and resuspended in a final concentration of 10^6 cells/ml in 20% FCS in RPMI. These cells were then used in the receptor function assay as described above.

REMOVAL OF CIRCULATING IMMUNE COMPLEXES FROM THE SERUM
In order to determine the effect of circulating immune complex-free serum on receptor function of monocytes from normal subjects, serum from patients with primary biliary cirrhosis and normal controls was treated with polyethylene glycol 6000 (Hopkin and Williams). Briefly, 6 ml of 20% polyethylene glycol in veronal buffered saline were mixed with 3 ml 0.2 M EDTA and 1 ml veronal buffered saline. This mixture was added to serum in a final concentration of 2% polyethylene glycol; after overnight incubation at 4°C, the mixture was centrifuged at 1720 g for 20 minutes at 4°C. The supernatant was collected in ice in separate tubes.

REMOVAL OF COMPLEMENT (C3) FROM THE SERUM
After depletion of circulating immune complexes from the serum, further removal of C3 was performed according to Hudson and Hay. Five hundred milligrams of zymosan (Sigma) were dissolved in 50 ml 0.9% sodium chloride at 100°C for 5 minutes, then centrifuged at 500 g for 10 minutes at 18°C. The supernatant was discarded and 10 ml of circulating immune complexes depleted serum was added to the precipitate, mixed, and incubated for one hour at 37°C, the suspension was spun at 1720 g for 20 minutes at 18°C and the supernatant was recovered. This procedure was repeated three times to ensure exhaustion of C3 and its degradation product C3b. Multiple zymosan treatments depleted completely C3 and C3b from sera obtained from both patients with primary biliary cirrhosis and normal controls as assessed by cross immuno-diffusion.

STATISTICAL METHODS
Wilcoxon's rank sum test for paired and unpaired values was used.

Results
MONOCYTE RECEPTOR FUNCTION
There was minimal binding of untreated sheep red blood cells and IgM coated sheep red blood cells to 100 monocytes isolated from controls (5.0±1.7, mean±1 SD and 5.8±2.0 respectively) and from the patients with liver disease: primary biliary cirrhosis 6.0±3.6 and 5.4±1.6, chronic active hepatitis 5.0±3.3 and 5.5±2.0 and alcoholic liver disease 4.5±1.0 and 6.5±1.0 respectively. There was no significant difference between the number of IgG1 coated sheep red blood cells attached to 100 monocytes isolated from controls (69.6±19.9) and monocytes isolated from patients with liver diseases: primary biliary cirrhosis (72.8±28.6), chronic active hepatitis (74.7±14.0) and alcoholic liver disease (58.0±13.5) (Fig. 1).

When the C3b receptor function was tested using IgM and complement coated sheep red blood cells, however, the number of such coated red cells attached to 100 monocytes from patients with primary biliary cirrhosis (23.0±12.0) was significantly lower than the number attached to 100 monocytes from normal controls (57.4±16.9) (p<0.01) or other liver disease groups: chronic active hepatitis (62.0±17.0) and alcoholic liver disease (50.9±4.0) (p<0.01) (Fig. 1).

Pre-incubation of serum from patients with primary biliary cirrhosis with mononuclear cells isolated from normal individuals had no effect on Fc-receptor function. The mean number of IgG1 coated sheep red blood cells attached to 100 monocytes was unchanged after incubation with serum from patients with primary biliary cirrhosis (55.8±8.9) compared with pre-incubation with serum from normal individuals (59.8±11.0). When the C3b receptor function was studied using IgM and complement coated sheep red blood cells, however, there was a significant reduction in the number of SRBC-M-C attached to 100 monocytes after pre-incubation with serum from patients with primary biliary cirrhosis (27.6±10.8) compared with pre-incubation with control serum (72.0±18.0) (p<0.05) (Fig. 2).

The number of IgM and complement coated sheep red blood cells attached to 100 normal monocytes remained significantly lower after pre-incubation with circulating immune complexes-depleted serum from patients with primary biliary cirrhosis (32.0±10.0) when compared with circulating immune complexes-depleted control serum (78.0±12.9) (p<0.05) (Fig. 2). In contrast the Fc receptor function of normal monocytes was unaltered by prior incubation with circulating immune complexes-depleted serum from either
Mononuclear cell complement receptor blockade in primary biliary cirrhosis

normal or primary biliary cirrhosis patients (67·0±10 SRBC-IgG₁/100 monocytes and 65·5±9·0 respectively). No effect of C₃ depletion of primary biliary cirrhosis serum on Fc receptor function of normal monocytes was observed. The number of SRBC-IgG₁ attached to 100 normal monocytes was 57·0±5·0 using C₃ depleted primary biliary cirrhosis serum compared with 65·9±9·0 before zymosan treatment and 71·6±8·0 using C₃ depleted normal serum. In contrast, the C₃b receptor function was found to be normal after zymosan treatment (64·0±11·8 SRBC-M-C/100 monocytes compared with 32·0±10·0 before zymosan treatment (p<0·05) (Fig. 2), with zymosan treated and untreated normal serum was not significantly different (81·5±15·0 and 78·0±12·9 respectively).

LYMPHOCYTE RECEPTOR FUNCTION

Lymphocytes remaining attached to petri dish were also examined for Fc and C₃b receptors after the various procedures described above. The results are summarised in Tables 1 and 2. The mean number of Fc receptors for IgG₁ (Fcγ₁ receptors) on the lymphocytes was similar in all the groups, whereas the mean number of C₃b receptors was lowest on the lymphocytes from patients with primary biliary cirrhosis. The C₃b receptors of normal lymphocytes could be masked in this assay by pre-incubation of mononuclear cells with serum from patients with
primary biliary cirrhosis, and the factor(s) responsible for this was not precipitated by polyethylene glycol treatment but could be depleted by treatment of the serum with zymosan.

**Discussion**

Phagocytosis by monocytes and macrophages remains poorly understood, although some of the processes involved are becoming clearer. Oposinised particles are attached to and ingested by means of receptors on the phagocytes. These receptors include both the Fc receptors which bind the Fc portion of aggregated or antigen complexed IgG and the complement receptors that bind particles coated with C₃b. Cooperation between these two receptors is necessary for efficient phagocytosis and blockade of either of these two receptors will reduce the phagocytic capacity. Patients with primary biliary cirrhosis, as with other chronic liver diseases investigated in this study, have normal functioning Fc receptors as assessed in our assay but, in contrast with the patients in the other groups, these patients have defective C₃b receptor function. While this defective function is likely to be because of blocking by serum factor(s), we were not able to exclude an intrinsic abnormality of the receptor itself. Intra-cellular assessment of marker molecules would be difficult since the cells will actively resynthesise depleted stores of glutathione and other such markers. Electron microscopy studies of membrane may help in testing this hypothesis. This receptor function defect is associated with a circulating serum factor because zymosan treatment had depleted the patients' sera of factors that block C₃b receptors of normal monocytes. The precise nature of this blocking factor is difficult to determine, but probably represents C₃ or C₉. This is because zymosan acts by cleaving C₃ into C₉a and C₉b and forming a complex with C₉b. Thus, in a small aliquot of serum, repeated incubation with zymosan and precipitation of the complex by centrifugation will deplete the serum of both C₃ and C₉b and this was confirmed by immunodiffusion. Indeed, preliminary studies had shown that a single exposure of serum from normal individuals with zymosan and subsequent centrifugation will result in that serum being able to block the C₉b receptor of monocytes from normal individuals.

In vitro manipulation of isolated monocytes may lead to activation of these cells which results in increased expression of receptors. An alternative explanation for these results is that C₉b receptors on monocytes from patients with primary biliary cirrhosis were not fully activated during isolation as were monocytes from the other groups. This is unlikely, however, because serum from patients with primary biliary cirrhosis could block C₉b receptors on monocytes from normal subjects.

Schreiber et al. found that hydrocortisone and prednisolone could inhibit in vitro both Fc and C₉b receptor function on monocytes from normal individuals. In our study, however, eight patients with chronic active hepatitis on corticosteroid therapy showed normal monocyte receptor function. These workers were using a concentration of corticosteroids a thousand times higher than those likely to be present in the serum of these patients.

In primary biliary cirrhosis increased concentrations of circulating immune complex-like activity and increased catabolism of complement have been reported. It was shown that circulating immune complexes of human serum albumin and anti-human serum albumin can cause a dose-dependent loss of both Fc and C₉b receptor function on rat Kupffer cells. These complexes are soluble, however, in contrast with those in the sera of patients with primary biliary cirrhosis which are insoluble and have different properties. It is of interest that there was no difference in the C₉b

---

**Table 1** Fcγ and C₉b receptor function of adherent lymphocytes isolated from normal controls and patients with primary biliary cirrhosis, chronic active hepatitis and alcoholic liver disease

<table>
<thead>
<tr>
<th>Lymphocytes from</th>
<th>Fcγ receptors (SRBC-IgG₁)</th>
<th>C₉b receptors (SRBC-M-C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control (10)</td>
<td>21.4±5.9</td>
<td>79.2±36.4</td>
</tr>
<tr>
<td>Primary biliary cirrhosis (13)</td>
<td>14.9±4.2</td>
<td>15.7±7.5*</td>
</tr>
<tr>
<td>Chronic active hepatitis (9)</td>
<td>18.2±6.4</td>
<td>68.8±25.9</td>
</tr>
<tr>
<td>Alcoholic liver disease (9)</td>
<td>15.3±4.6</td>
<td>75.6±31.4</td>
</tr>
</tbody>
</table>

* p<0.01 compared with control lymphocytes; figures given are mean±1 SD.

---

**Table 2** Effect of lymphocyte Fcγ and C₉b receptor function of prior incubation of normal lymphocytes with normal serum and serum from patients with primary biliary cirrhosis (PBC) and after depletion of circulating immune complexes (CIC) and complement (C₃)

<table>
<thead>
<tr>
<th>Lymphocytes from normal control after pre-incubation</th>
<th>Fcγ receptors (SRBC-IgG₁)</th>
<th>C₉b receptors (SRBC-M-C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal human serum (6)</td>
<td>20±5.6</td>
<td>78.6±20</td>
</tr>
<tr>
<td>PBC serum</td>
<td>17±6.4</td>
<td>36.3±10.7*</td>
</tr>
<tr>
<td>NHS depleted CIC (6)</td>
<td>16±3±6.6</td>
<td>98±1±6.3</td>
</tr>
<tr>
<td>PBC sera depleted CIC (6)</td>
<td>13±5±3.8</td>
<td>26±5*</td>
</tr>
<tr>
<td>NHS depleted CIC and C₃ (6)</td>
<td>21±4.5</td>
<td>81.5±15</td>
</tr>
<tr>
<td>PBC sera depleted CIC and C₃</td>
<td>14±5±3.7</td>
<td>76±12.9</td>
</tr>
</tbody>
</table>

* p<0.05 compared with controls; figures are mean±SD.

---

**Al-Aghbar, Neuberger, Williams, and Eddleston**
receptor function in those patients receiving d-penicillamine compared with those on no specific therapy, even though d-penicillamine therapy may be associated with reduction in circulating immune complexes. These findings add further support to the results that removal of circulating immune complexes from sera of patients with primary biliary cirrhosis does not alter the ability of the serum to block the C3b receptor on normal monocytes. The finding that the C3b receptors on lymphocytes isolated from patients with primary biliary cirrhosis are blocked by factors other than immune complexes parallel the results obtained on the monocyte receptors. The lymphocytes studied, however, were those adherent to the petri dishes and are unlikely to be representative of the lymphocyte populations in either the patient's blood or liver. Nevertheless, the results do suggest that at least some of the factors which block the monocyte C3b receptors may block some of the lymphocyte C3b receptors.

While the pathogenesis of primary biliary cirrhosis remains unclear, defective phagocytosis caused by impaired C3b receptor function may lead to persistence of antigenic challenge and increase in antibody production. This may result in the formation of increased concentrations of circulating immune complexes which may lead to complement activation and granuloma formation, and could contribute to the pathogenesis of the disease.

JN is a Wellcome clinical research fellow. We are indebted to Dr Diego Vergani, Department of Immunology, King's College Hospital for technical advice and to Linda Rimmer for editorial assistance.

References

Mononuclear cell complement receptor blockade in primary biliary cirrhosis.
M N Al-Aghbar, J Neuberger, R Williams and A L Eddleston

Gut 1985 26: 20-25
doi: 10.1136/gut.26.1.20

Updated information and services can be found at:
http://gut.bmj.com/content/26/1/20

Email alerting service
These include:
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/